Apolin

Quick links to important sections

Apolin

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Apolin

Understanding Apolin: Identity and Pharmacological Type

Property Description
Active ingredient Hydralazine hydrochloride
Forms Oral tablets, Injectable solution
Pharmacological class Antihypertensive agent, Direct-acting Vasodilator
General purpose Lowering elevated blood pressure
Origin Synthetic organic compound

Apolin is a trade designation for the prescription medication containing the active ingredient Hydralazine hydrochloride, a compound used for circulatory management. This substance is a synthetic organic compound derived from the Hydrazinophthalazine class. Its clinical distinction is its role as a direct-acting vasodilator.

The foundational principle of Apolin’s action lies in this classification and its ability to influence vascular tone. Its mechanism involves directly causing the relaxation of the smooth muscle surrounding the body’s peripheral arterioles. This action physiologically widens the blood vessels (vasodilation), creating less resistance to blood flow. Hydralazine reduces resistance in the peripheral blood vessels, establishing its specialized role. The primary therapeutic focus for this type of agent is achieving the lowering of elevated systemic blood pressure.

Composition, Forms, and General Purpose

The medicinal entity Apolin is a single active ingredient product, supplied as oral tablets and a sterile injectable solution. This dual-form profile provides clinical flexibility; the oral tablets are suitable for sustained, long-term maintenance, while the injectable solution is reserved for settings requiring rapid control.

This composition ensures that the antihypertensive effect of Hydralazine can be delivered effectively, whether via the digestive tract or directly into the bloodstream. The drug's general purpose is centered on reducing peripheral vascular resistance. For a patient, the benefit is supporting cardiac function by ensuring the heart does not have to strain against excessive resistance when pumping blood throughout the body.

Regulatory References

  1. World Health Organization (WHO)
  2. U.S. National Library of Medicine

What side effects are possible with Apolin?

Possible Side Effects and Safety Information

Apolin (Hydralazine hydrochloride) is associated with an official safety profile that reflects its primary action as a direct-acting vasodilator. The documented adverse reactions are categorized by frequency and System Organ Class (SOC) based on regulatory standards.

Frequency-Classified Adverse Reactions

Certain effects are classified based on observed incidence in clinical data:

  • Very Common: These effects, which include tachycardia (rapid heartbeat), palpitations, and headache, are often observed at the start of treatment or during dose escalation but typically subside later.
  • Common: Adverse reactions such as hypotension, flushing, anginal symptoms, diarrhoea, and arthralgia (joint pain) are frequently documented.
  • Very Rare: These include serious haematological events like agranulocytosis and the potential development of a Systemic Lupus Erythematosus (SLE)-like syndrome.

Serious Safety Considerations

The official labeling documents several important safety constraints and serious adverse reactions.

1. Duration-Related Risk: Prolonged exposure, typically defined as treatment exceeding six months, is associated with the risk of provoking the Systemic Lupus Erythematosus (SLE)-like syndrome. The risk is officially noted as being higher in individuals who are slow acetylators.

2. Contraindications: The use of Apolin is officially contraindicated in patients with established Coronary Artery Disease and Mitral Valvular Rheumatic Heart Disease.

3. Population-Specific Notes: The label includes specific safety notes for individuals with Renal Impairment, advising caution due to altered elimination. Furthermore, newborns of mothers who received this medicine have been reported to experience adverse haematological effects, such as thrombocytopenia.

Overdose and Emergency Response

Overdose and when to seek help: Official Regulatory Information for Apolin

Regulatory documents define the signs and clinical manifestations of an Apolin (Hydralazine) overdose, which primarily reflect severe cardiovascular compromise. The documented presentation of an acute overdose includes hypotension (extremely low blood pressure), pronounced tachycardia (rapid heart rate), headache, and generalized skin flushing. These manifestations serve as official indicators of an overdose event.

Overdosage carries the risk of severe, life-threatening outcomes, including profound shock, cardiac arrhythmia, myocardial ischemia (inadequate blood flow to the heart muscle), and subsequent myocardial infarction. Due to these serious complications, the official labeling mandates immediate medical attention for any suspected overdose event. Emergency services must be contacted immediately if severe symptoms are observed, such as collapse, seizure, trouble breathing, or the inability to be awakened.

The regulatory text confirms that no specific antidote is known for an Apolin overdose. The management protocol described in the prescribing information focuses on support of the cardiovascular system as the primary therapeutic necessity. Treatment for shock involves administering plasma expanders (volume replacement), and beta blockers may be utilized to manage tachycardia. Regulatory guidance notes that vasopressors should not be given if possible but, if required, must be administered with extreme caution due to the risk of aggravating cardiac arrhythmia.

Therapeutic Uses of Apolin

What Apolin treats: main uses and benefits

Apolin is formulated to assist in the temporary management of a range of common symptoms and conditions associated with minor ailments. Its purpose is focused on managing discomfort associated with various health issues. Common uses include temporary relief from headache, muscle aches, fever, and minor pain often linked to the common cold or flu.

Reports indicate that Apolin may help individuals manage daily activities when experiencing symptoms, supporting general function. The drug is commonly used in scenarios where general pain and fever need to be addressed when symptoms arise.

Quick Fact: Relief for Headache and Fever

Eligibility and Restrictions for Use

Official Eligibility Rules for Apolin (Hydralazine)

Regulatory agencies strictly define the populations eligible to use Apolin, primarily based on the patient’s pre-existing conditions and demographic status. Use is governed by specific contraindications and conditional restrictions.

Contraindicated Populations

Apolin is absolutely contraindicated and must not be used in individuals with a known hypersensitivity to the drug, or those diagnosed with specific cardiovascular conditions, including Coronary Artery Disease, Mitral Valvular Rheumatic Heart Disease, and certain cardiac mechanical obstructions. Use is also prohibited in patients with Idiopathic Systemic Lupus Erythematosus (SLE).

Age and Organ Function Restrictions

Population Regulatory Status
Pediatric Patients Safety and effectiveness are not established by controlled clinical trials.
Renal/Hepatic Impairment Requires mandatory dose or interval adjustment to prevent drug accumulation.
Pregnancy Not recommended during the first two trimesters; conditionally permitted in the third trimester for severe maternal conditions like pre-eclampsia.

Patients with Angina Pectoris or recent Myocardial Infarction require restricted or delayed use.

What should I know about interactions with other medicines?

Apolin Interactions with other medicines and products

The official regulatory profile for Apolin (Hydralazine hydrochloride) outlines specific pharmacokinetic and pharmacodynamic interactions. Co-administration with other antihypertensive agents, including diuretics, beta-blockers, and ACE inhibitors, results in a pharmacodynamic potentiation that causes additive hypotensive effects. Similarly, concomitant use with Alcohol (Ethanol) may lead to additive blood pressure-lowering effects. Non-steroidal Anti-inflammatory Drugs (NSAIDs) and Oestrogens are documented to potentially antagonise the drug's hypotensive effect.

Apolin may also modify the exposure of co-administered medicines. The label specifies that Apolin can increase the bioavailability of certain beta-blockers subject to a strong first-pass effect. Furthermore, the product has the potential to elevate the plasma levels of co-administered drugs metabolized by the CYP3A4 enzyme system.

Administration is tied to a pharmacokinetic rule, as the oral formulation must be co-administered with food to improve its bioavailability. Regarding procedural constraints, Adrenaline (Epinephrine) is restricted from use to correct hypotension during surgery, as it enhances the cardiac-accelerating effects. Population-specific considerations are noted for patients with advanced renal damage, who may experience increased hypotensive effects due to slower removal of the drug from the body.

Mechanism of Action

Apolin functions as an agonist for the Apelin Receptor (APJ), a G protein-coupled receptor (GPCR) expressed across cardiovascular tissues, adipose tissue, and the central nervous system. Binding of Apolin to the APJ receptor induces a conformational change that primarily promotes coupling to Gi/o proteins.

Activation of the Gi/o protein complex initiates multiple intracellular pathways. The alphai/o subunit inhibits adenylyl cyclase, resulting in a reduction of cyclic adenosine monophosphate (cAMP) levels and subsequent downregulation of Protein Kinase A (PKA) activity. Concurrently, the betagamma subunits trigger the activation of the Phosphatidylinositol 3-kinase (PI3K)/Akt pathway and the Extracellular signal-regulated kinase 1/2 (ERK 1/2) pathway. APJ activation also engages Gq protein signaling, which subsequently activates Phospholipase C beta (PLCbeta), leading to the generation of Inositol trisphosphate (IP3) and Diacylglycerol (DAG). IP3 mediates the release of intracellular Ca^2+, a mechanism involved in regulating Ca^2+-dependent Nitric Oxide Synthase (NOS) activity.

System-level consequences include modulation of cardiac contractility, peripheral vasodilation via vascular smooth muscle relaxation, and regulation of fluid homeostasis.

Dosage and Administration Information

How Apolin is Used

Apolin, which contains hydralazine, is utilized via distinct protocols based on the administration route and clinical setting. It is provided in two main forms: oral tablets for long-term management and a sterile injectable solution for acute, urgent situations requiring rapid response.


Oral Dosing and Titration

Oral administration typically begins with a low dose, such as 10 mg four times daily (QID), which is then gradually and stepwise increased over a period of one to two weeks. The common maintenance dose often reaches 50 mg QID. The dose generally does not exceed 200 mg daily in divided doses. To maintain consistent absorption, the practice involves taking the tablets consistently with respect to food—either always with food or always without.


Parenteral and Specialized Use

For urgent needs, the injectable solution is administered intravenously or intramuscularly at a starting dose of 10 mg to 20 mg, and this administration is reserved for settings with close medical supervision. Patients receiving the injectable form are intended to be transitioned to oral therapy as soon as their condition allows. For those with renal or hepatic impairment, clinical practice involves adjusting the dose or interval to prevent drug accumulation. Furthermore, if a daily oral dose is to exceed 100 mg, clinical considerations may include the patient’s acetylator status.

Recent Clinical Evidence

Research evidence / Overview of Studies for Apolin (Hydralazine)

Evidence for use in Essential Hypertension

Apolin was studied for the management of high blood pressure, specifically in cases where other initial treatments did not achieve the desired outcome. The research base for this use primarily consists of older Randomized Controlled Trials (RCTs) and long-term observational studies exploring its role, primarily as an add-on therapy. These studies were evaluated in adult populations with high blood pressure, including those with resistant hypertension. The research mainly examined the effect of adding Apolin to existing medication regimens.

Findings describe patterns observed in the studies related to blood pressure changes when Apolin was observed in combination with other agents, such as diuretics or beta-blockers. Limited comparative evidence is lacking that directly evaluates Apolin against other currently available antihypertensive drugs. Follow-up durations were limited in some studies, meaning there is limited information for long-term outcomes when Apolin is used in modern treatment sequences.


Evidence for use in Chronic Heart Failure (HFrEF) Combination Therapy

The research supporting Apolin's use in chronic heart failure (HFrEF) is derived from pivotal, large-scale studies exploring its use in combination with another medication, isosorbide dinitrate. Pivotal Randomized Controlled Trials (RCTs) contributed significantly to the evidence base, examining hundreds of patients with symptomatic heart failure. These studies primarily monitored hard outcomes, such as All-Cause Mortality and the frequency of Heart Failure Hospitalization.

Research in this area also included measurements during the study period concerning the heart's pumping ability (ejection fraction). The evidence described in the key trials applies only to the populations studied and to the combination of Apolin and Isosorbide Dinitrate. The pivotal trials did not examine Apolin alone for heart failure management. Data for certain groups remain insufficient, particularly for patients who did not fit the specific demographic profile that was the focus of the largest, most definitive trial.

Frequently Asked Questions (FAQ)

Common questions about Apolin (FAQ)


Q: How long can a person stay on Apolin?

According to official regulatory documents, prolonged use of Apolin, typically defined as treatment exceeding six months, is associated with a specific safety consideration. This duration is linked to the risk of developing a condition known as a Systemic Lupus Erythematosus (SLE)-like syndrome. Your healthcare provider assesses this risk when determining the overall treatment plan.


Q: Can Apolin be taken with other pain relievers?

Official product information describes that co-administration with Non-steroidal Anti-inflammatory Drugs (NSAIDs) can lead to an interaction. NSAIDs are documented to potentially lessen Apolin's intended blood pressure-lowering effect. Patients are generally advised to inform their healthcare professional about all pain relievers they use, including over-the-counter options.


Q: How quickly does Apolin usually start working?

Studies and official information indicate that the blood pressure-lowering effect of the active ingredient typically begins relatively quickly, within 10 to 30 minutes after administration. This effect is generally observed to last for a duration of approximately 2 to 4 hours, which is a factor in determining the frequency of administration.


Q: What happens if I stop taking Apolin suddenly?

Official information notes that abruptly stopping this medication is generally not recommended without instruction from a healthcare provider. For certain conditions, immediate discontinuation may cause the condition to worsen. When the medication needs to be stopped, regulatory guidance indicates that the dose may require gradual reduction.


Q: Is Apolin safe for people with kidney problems?

Regulatory guidance states that caution is required for individuals with advanced renal impairment (kidney problems). Because the drug is removed from the body more slowly in these patients, official labels mandate that the dose or interval may need to be adjusted by a healthcare professional.


Q: Can Apolin interact with common vitamins or supplements?

While the official interaction section focuses on certain medications, general patient information notes that disclosing all products used to a healthcare professional is standard practice. This includes all prescribed medicines, as well as over-the-counter drugs, vitamins, and herbal supplements, to screen for potential interactions.


Q: Do studies suggest Apolin is safe during pregnancy?

Official labeling places the drug in Pregnancy Category C. It is generally not recommended for use during the first two trimesters of pregnancy. However, its use may be conditionally permitted in the third trimester for specific severe maternal conditions, such as pre-eclampsia.


Q: Can Apolin be taken on an empty stomach?

To ensure the drug is absorbed consistently, official administration rules recommend taking the tablets consistently with respect to food. This means the prescribed approach should be to either always take the medicine with food or always take it without food to maintain steady bioavailability.


Q: Is Apolin a type of antibiotic?

No, Apolin is not classified as an antibiotic. The active ingredient is officially categorized as a direct-acting vasodilator, which is a type of antihypertensive agent. Its purpose is related to circulatory management and lowering blood pressure.


Q: Are there any specific foods to avoid while taking Apolin?

Official drug information identifies an interaction concern with grapefruit juice. Like many medications, compounds in grapefruit may affect how the body processes Apolin, potentially leading to increased drug exposure. It is standard practice to discuss any dietary changes or specific food concerns with a healthcare professional.


Q: Does Apolin make you tired or drowsy?

Official safety information lists side effects such as dizziness, faintness, and lightheadedness. These effects are often related to its action of lowering blood pressure, and they are noted as potentially affecting one’s ability to drive or operate machinery.


Q: Can Apolin be used by people over 65?

Clinical evidence suggests that, in general, no special dosage regimen is typically necessary for elderly patients. However, because kidney function often diminishes with age, a patient's renal status is considered during administration, as this affects the body's elimination of the drug.


Q: Is there a generic version of Apolin available?

Yes, the active ingredient in Apolin, Hydralazine hydrochloride, is a well-established medication. It is generally available in the market as a generic tablet formulation, in addition to the brand-name product.


Q: What is the approved use of Apolin in children?

Regulatory documents state that the safety and effectiveness of Apolin in pediatric patients (children) are officially not established by controlled clinical trials.


Q: Are there any known interactions between Apolin and alcohol?

Yes, official product information documents an interaction with alcohol (ethanol). Concomitant use may result in an additive hypotensive effect, which means combining them could cause a greater-than-expected reduction in blood pressure.


Q: Why do official documents warn about taking Apolin with grapefruit juice?

The warning exists because compounds found in grapefruit can interfere with the body's metabolic processes that break down Apolin. This interference can potentially increase the amount of the medicine in the bloodstream, altering its effect.


Q: Does research show Apolin is effective for long-term use?

Research has examined the use of Apolin in chronic conditions like essential hypertension and chronic heart failure. While the evidence supports its role, official summaries also note that some studies have had limited follow-up durations, meaning long-term outcomes are not fully established in all contexts.


Q: Is Apolin used for chronic conditions?

Yes, the active ingredient in Apolin has been studied and is utilized in the management of chronic, long-term conditions. This includes its use in combination therapy for Chronic Heart Failure (HFrEF) and for managing essential hypertension (high blood pressure).


Q: Can Apolin interact with herbal teas?

Regulatory patient information describes that patients are generally expected to disclose the use of herbal products, including teas, to their healthcare professional. This is a general safety requirement to screen for potential unknown interactions with the medication.


Q: Is Apolin known to affect mood?

Official safety data lists feeling anxious or depressed as possible adverse reactions, although they are noted to be less common. Unusual or persistent changes in mood are generally matters for discussion with a healthcare provider.


Q: Why might a doctor switch me from one drug to Apolin?

Research summaries describe Apolin's role in managing high blood pressure, particularly in cases where other initial treatments did not achieve the desired outcome. For this reason, it is often studied and used as an add-on therapy for conditions like resistant hypertension.


Q: Are the side effects of Apolin usually temporary?

Official safety data indicates that the most commonly reported side effects, such as rapid heartbeat (tachycardia) and headache, are often observed when treatment begins. These Very Common effects are noted to typically subside later as the body adjusts to the medication.


Q: What information is publicly available about the clinical trials for Apolin?

The evidence base supporting Apolin includes publicly accessible information derived from pivotal, large-scale studies and Randomized Controlled Trials (RCTs). These trial summaries detail monitored outcomes such as all-cause mortality and heart failure hospitalization frequency.


Q: How often do patients typically take Apolin?

Oral administration is typically prescribed as divided doses taken multiple times per day. The official labeling describes regimens most commonly involving doses taken four times daily (QID).


Q: Is Apolin meant to be taken every day?

The oral tablet form is specifically prescribed for sustained, long-term maintenance of a patient's condition. For the duration it is prescribed, this implies the medicine is intended for continuous, daily use.


Q: Can I drive while taking Apolin?

Official labeling advises caution regarding driving or operating heavy machinery. This is because the drug can cause side effects like dizziness or lightheadedness, and patients are advised to wait and see how the medication affects them before undertaking these activities.


Q: What is the half-life of Apolin?

The pharmacokinetics section of official labeling describes the plasma half-life. For individuals with normal kidney function, the half-life is typically noted as ranging from 3 to 7 hours.

How should Apolin be stored and disposed of?

Official Storage and Disposal Requirements

Storage Conditions

Apolin (Hydralazine hydrochloride) tablets must be stored at controlled room temperature, typically 20 C to 25 C (68 F to 77 F). The product must be kept in its original, tightly closed container and protected from light and moisture. The injectable solution must be stored below 25 C (77 F) and must not be frozen.

Stability and Handling

The medicine must be stored out of the reach and sight of children. The injectable solution must be diluted just prior to use, as the prepared solution has a limited stability period. Inspect the injection for discoloration before use.

Disposal

Unused or expired Apolin should be discarded using an authorized drug take-back program. If this option is unavailable, the product must be mixed with an undesirable substance, placed in a sealed bag, and disposed of in the household trash. It must not be flushed down the toilet.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Apolin found in:

A-Z Index: